ライフサイエンスコーパス: HIV antigen

1 maintained by ongoing systemic expression of HIV antigen.

2 , 77% to >=1 non-HIV antigen, and 11% to >=1 HIV antigen.

3 nd target cell infection and presentation of HIV antigens.

4 ith increased concentration and affinity for HIV antigens.

5 f these cells had recently been activated by HIV antigens.

6 urable cellular immune responses to multiple HIV antigens.

7 IV) to load human dendritic cells (DCs) with HIV antigens.

8 esponses were specific for canarypox but not HIV antigens.

9 lated with higher proliferative responses to HIV antigens.

10 for expressing human immunodeficiency virus (HIV) antigens.

11 with purified human immunodeficiency virus (HIV) antigens.

12 -generation assays by definition detect both HIV antigen and antibody.) The clinical and sociodemogra

13 on of intracellular IFN-gamma in response to HIV antigens and HLA B*57-gag tetramer staining.

14 s (LPR) were measured to various HIV and non-HIV antigens and mitogens using peripheral blood mononuc

15 w abundance antibodies specific to different HIV antigens and rare HIV-specific cells from blood obta

16 Changes in lymphoproliferative responses to HIV antigens and recall antigens did not increase over t

17 on between CTL activity for each of the four HIV antigens and viral load was observed among individua

18 ersons responded to mitogens, 77% to >=1 non-HIV antigen, and 11% to >=1 HIV antigen.

19 assays: fourth-generation enzyme immunoassay HIV antigen-antibody combination, HIV-1 and HIV-2 rapid

20 arlier in the course of their infection with HIV antigen/antibody (Ag/Ab) combination assays (4th-gen

21 s remain stable after multiple passages, and HIV antigens are correctly expressed and released from c

22 s that express human immunodeficiency virus (HIV) antigens are being developed as potential vaccines

23 s factor alpha) of CD4+ T cells specific for HIV antigens as well as for adenovirus, Epstein-Barr vir

24 infected H9 lymphocytic cells were producing HIV antigens by immunofluorescent assay, most lymphocyte

25 sfected with mRNA encoding lysosome-targeted HIV antigen can expand a broad, polyclonal repertoire of

26 activity, proliferative CD4 cell response to HIV antigens, CD8 cell production of macrophage inflamma

27 In the present study we use a model HIV antigen (CN54gp140) conjugated to transferrin (Tf) a

28 nes induced immune responses against a model HIV antigen comparable to electroporation in mice, enhan

29 For example, self-tumor or HIV antigens genetically fused with proinflammatory chem

30 the IgA antibodies and IgA antibodies to non-HIV antigens had no HIV excretory function.

31 ented LPR of HIV-seropositive persons to non-HIV antigens; however, the effect was greatest for those

32 Addition of IL-12 also enhanced LPR to HIV antigens in 30% of subjects.

33 ced cellular and humoral immune responses to HIV antigens in both groups, though the reduction was gr

34 nv is commonly used as part of a cocktail of HIV antigens in current vaccines.

35 +) patients demonstrated increased basal and HIV antigen-induced expression of the early apoptosis ma

36 ific CD8) and B cell immune responses to the HIV antigens, leading to high antibody titers against gp

37 Thus, CTL responding to different HIV antigens may not be contributing equally to the prev

38 strong lymphocyte-proliferative responses to HIV antigens or antibodies to many viral epitopes.

39 d explore how rapid tests to directly detect HIV antigens or nucleic acids might alter current approa

40 e of detecting human immunodeficiency virus (HIV) antigens or nucleic acids represent the possibility

41 produce a recombinant biopharmaceutical, the HIV antigen P24.

42 itro assembly system which allows display of HIV antigens, p24-gag, Nef, and an engineered gp41 C-pep

43 by CD4(+) and CD8(+) T cells in response to HIV antigens/peptides in vitro; these effects were cell

44 8 expression affects immune responses to non-HIV antigens, potentially contributing to susceptibility

45 n of IgG specific for selected transmembrane HIV antigens provides a simple and reliable test that is

46 memory T cells to proliferate in response to HIV antigens rather than an absolute loss of circulating

47 However, responses to an HIV antigen remained depressed, and the production of in

48 nal in T cell stimulation assays and induced HIV antigen-specific CD8(+) T cell production of IFN-gam

49 s, adoptive transfer of genetically modified HIV-antigen-specific T cells was safe.

50 ither bulk CXCR5(+) CD4(+) T cells nor other HIV antigen specificities were associated with gp120-spe

51 uction of HIV-suppressive beta-chemokines by HIV antigen-stimulated PBMC was significantly higher in

52 ete cytokines and proliferate in response to HIV antigen stimulation.

53 Env binding antibodies, compared with other HIV antigens (such as p24) or tetanus toxoid.

54 total responses of ELISPOT-forming cells to HIV antigens than do children who are treated later in l

55 ound p24gag (referred to as p24 in the text) HIV antigen through secretory IgA (SIgA) in nasal mucosa

56 ty complex class II (MHC-II) presentation of HIV antigens to CD4 T cells.

57 steria to infect human monocytes and present HIV antigens to CD8 T lymphocytes of HIV-infected donors

58 tem, recombinant constructs encoding several HIV antigens up to 500 amino acids were produced.

59 ducing cells, IL-2 production in response to HIV antigens was diminished during viremia.

60 even though their capacity to proliferate to HIV antigens was preserved only in LTNP.

61 Using HIV antigens, we found that administering a given total

62 In each case, proliferative responses to HIV antigens were rapidly inhibited during viremia.

63 that memory B-cell responses to HIV and non-HIV antigens were superior in early- compared with chron

64 uld be induced to proliferate in response to HIV antigens when costimulation was provided by anti-CD2

65 ell interactions of NYVAC vectors expressing HIV antigens, with the activation of specific immune par